SPRAVATO® (Esketamine Nasal Spray)

A prescription treatment for adults with treatment-resistant depression.

What Is SPRAVATO®?

SPRAVATO® is a prescription nasal spray containing esketamine — a medication derived from ketamine, approved by the FDA for use in adults with treatment-resistant depression (TRD). Unlike traditional antidepressants that take weeks to work and target serotonin pathways, SPRAVATO® acts on the glutamate system, offering a new mechanism for relieving depressive symptoms.

SPRAVATO® is used in combination with an oral antidepressant and must be administered in a certified clinical setting under medical supervision. It’s not a take-home medication — but it may offer fast-acting relief for people who haven’t responded to standard treatments.

Conditions SPRAVATO® May Help With

SPRAVATO® is FDA-approved specifically for:

Treatment-Resistant Depression (TRD)

Major depressive disorder that hasn’t improved after trying at least two different antidepressants

This treatment is not intended for general anxiety, OCD, PTSD, or other psychiatric conditions. All patients must meet diagnostic criteria for TRD and be evaluated by a licensed prescriber before beginning treatment.

Who Might Benefit From SPRAVATO®

You may be a candidate for SPRAVATO® if:

You’ve tried two or more antidepressants without meaningful or lasting improvement

You continue to experience symptoms of depression despite medication and/or therapy

Side effects from past medications have made ongoing treatment difficult

You’re seeking a new approach after exhausting other options

SPRAVATO® is not for everyone. A consultation with a certified provider is required to assess your safety and eligibility.

How the Treatment Works

SPRAVATO® is administered via a nasal spray device under direct supervision at a certified clinic. You’ll self-administer the dose under guidance, and then remain on-site for monitoring.

Here’s what the process typically looks like:

Treatment Frequency:

In-Clinic Monitoring:

Supportive Care:

Safety and Side Effects

SPRAVATO® is a controlled medication and must be administered in a certified Risk Evaluation and Mitigation Strategy (REMS) program clinic due to its potential side effects and dissociative effects.

Common side effects may include:

Dizziness or nausea

Increased blood pressure

Feeling disconnected or sedated during treatment

Headache or fatigue afterward

Your care team will monitor you before, during, and after each session. You’ll undergo medical screening before treatment and regular assessments throughout your care plan.

What to Expect From Results

SPRAVATO® works differently than traditional antidepressants — and often faster. Many patients begin noticing improvements in mood, energy, or emotional clarity within the first few weeks.

Here’s what to keep in mind:

SPRAVATO® is designed for people with TRD, so early improvements are promising but not guaranteed

Like all treatments, response varies from person to person

Ongoing evaluation is built into the treatment plan to ensure safety and effectiveness

If effective, SPRAVATO® may reduce depressive symptoms and improve daily functioning

Why Lumora

Lumora is not a clinic — we help connect you to qualified providers who offer advanced psychiatric treatments like SPRAVATO®. Our network includes trusted clinics with licensed professionals who follow the FDA’s strict administration protocols.

When you start your SPRAVATO® journey through Lumora, you can expect:

A clear explanation of what to expect before your first visit

Clinics that follow FDA REMS guidelines for safety and oversight

Ongoing communication and support from start to finish

Guidance about how SPRAVATO® fits into your broader care plan

You’ve done the work — let us help you take the next step.